MX375061B - Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina. - Google Patents

Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.

Info

Publication number
MX375061B
MX375061B MX2015009311A MX2015009311A MX375061B MX 375061 B MX375061 B MX 375061B MX 2015009311 A MX2015009311 A MX 2015009311A MX 2015009311 A MX2015009311 A MX 2015009311A MX 375061 B MX375061 B MX 375061B
Authority
MX
Mexico
Prior art keywords
retina
treatment
degenerative diseases
improved modalities
retinal
Prior art date
Application number
MX2015009311A
Other languages
English (en)
Spanish (es)
Inventor
Irina V Klimanskaya
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of MX375061B publication Critical patent/MX375061B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Analytical Chemistry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
MX2015009311A 2004-01-23 2005-01-24 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina. MX375061B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53896404P 2004-01-23 2004-01-23
PCT/US2005/002273 WO2005070011A2 (en) 2004-01-23 2005-01-24 Improved modalities for the treatment of degenerative diseases of the retina

Publications (1)

Publication Number Publication Date
MX375061B true MX375061B (es) 2025-03-06

Family

ID=34807248

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2015009311A MX375061B (es) 2004-01-23 2005-01-24 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.
MX2014001634A MX375065B (es) 2004-01-23 2005-01-24 Composiciones para usarse en el tratamiento de enfermedades degenerativas de la retina.
MX2020009456A MX2020009456A (es) 2004-01-23 2006-07-21 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.
MX2011006096A MX343606B (es) 2004-01-23 2006-07-21 Composiciones para el tratamiento de enfermedades degenerativas de la retina.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2014001634A MX375065B (es) 2004-01-23 2005-01-24 Composiciones para usarse en el tratamiento de enfermedades degenerativas de la retina.
MX2020009456A MX2020009456A (es) 2004-01-23 2006-07-21 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.
MX2011006096A MX343606B (es) 2004-01-23 2006-07-21 Composiciones para el tratamiento de enfermedades degenerativas de la retina.

Country Status (15)

Country Link
US (6) US7736896B2 (cg-RX-API-DMAC7.html)
EP (8) EP4248752A3 (cg-RX-API-DMAC7.html)
JP (10) JP2007522131A (cg-RX-API-DMAC7.html)
KR (3) KR101258292B1 (cg-RX-API-DMAC7.html)
CN (3) CN104434979A (cg-RX-API-DMAC7.html)
AU (6) AU2005207042B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0507074A (cg-RX-API-DMAC7.html)
CA (2) CA2937099A1 (cg-RX-API-DMAC7.html)
ES (1) ES2721174T3 (cg-RX-API-DMAC7.html)
HK (2) HK1216068A1 (cg-RX-API-DMAC7.html)
IL (3) IL177015B (cg-RX-API-DMAC7.html)
MX (4) MX375061B (cg-RX-API-DMAC7.html)
NZ (1) NZ548929A (cg-RX-API-DMAC7.html)
SG (4) SG155236A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005070011A2 (cg-RX-API-DMAC7.html)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043614B2 (en) * 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
EP4248752A3 (en) 2004-01-23 2024-01-03 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP1812554A4 (en) 2004-11-04 2008-10-08 Advanced Cell Tech Inc DERIVATION OF EMBRYONAL STEM CELLS
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
US7541186B2 (en) * 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
KR20150142061A (ko) 2006-05-03 2015-12-21 오카타 세라퓨틱스, 인크. 배아 줄기 세포 및 배-유도 세포의 유도
US9133435B2 (en) * 2007-01-18 2015-09-15 Riken Method for induction/differentiation into photoreceptor cell
CA2679109C (en) 2007-02-23 2016-07-19 Advanced Cell Technology, Inc. Derivation of embryonic stem cells
WO2008129554A1 (en) * 2007-04-18 2008-10-30 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
WO2008137115A1 (en) 2007-05-03 2008-11-13 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
KR101849329B1 (ko) * 2007-10-12 2018-04-16 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Ｒｐｅ 세포의 개선된 생산 방법 및 ｒｐｅ 세포의 조성물
AU2015201435B2 (en) * 2007-10-12 2017-02-02 Astellas Institute For Regenerative Medicine Improved methods of producing RPE cells and compositions of RPE cells
WO2009132156A1 (en) * 2008-04-22 2009-10-29 Regenerative Research Foundation Retinal pigment epithelial stem cells
WO2011028524A1 (en) 2009-08-24 2011-03-10 Wisconsin Alumni Research Foundation Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
EP3549617B1 (en) 2010-07-12 2023-09-13 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
HUE054517T2 (hu) 2010-07-23 2021-09-28 Astellas Inst For Regenerative Medicine Eljárások sejtek ritka alpopulációinak detektálására és nagymértékben tisztított sejtkészítmények
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US10478206B2 (en) 2011-04-29 2019-11-19 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
AU2012256014B2 (en) 2011-05-13 2016-10-27 Elixirgen, Llc Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
CN111265551A (zh) * 2011-05-18 2020-06-12 加利福尼亚大学董事会 用于治疗视网膜疾病的组合物及方法
WO2013015835A1 (en) 2011-07-22 2013-01-31 Seven Networks, Inc. Mobile application traffic optimization
CN103007355B (zh) * 2011-09-20 2014-08-13 同济大学 一种水凝胶-纳米纤维膜及其制备方法和用途
IL320536A (en) 2011-11-14 2025-06-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human RPE cells and their use
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CA2857545A1 (en) 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
CN104136601A (zh) * 2012-02-17 2014-11-05 斯格本斯眼科研究所 人视网膜祖细胞的表型谱
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
WO2014011407A2 (en) 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
US11033586B2 (en) * 2012-08-24 2021-06-15 Riken Method for producing retinal pigment epithelial cell sheet
CN118995611A (zh) 2013-03-15 2024-11-22 安斯泰来再生医药协会 由多能干细胞产生的光感受器和光感受器祖细胞
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP2980207B1 (en) * 2013-03-25 2018-12-05 Foundation for Biomedical Research and Innovation at Kobe Cell sorting method
EP2796545A1 (en) * 2013-04-26 2014-10-29 Université Pierre et Marie Curie (Paris 6) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
ES2763433T3 (es) 2013-11-27 2020-05-28 Kyoto Prefectural Public Univ Corp Aplicación de laminina a cultivos de células endoteliales de la córnea
WO2015087231A1 (en) 2013-12-11 2015-06-18 Pfizer Limited Method for producing retinal pigment epithelial cells
US11633477B2 (en) 2014-10-31 2023-04-25 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
EP3213761B1 (en) * 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
SG10201907918VA (en) 2015-03-23 2019-10-30 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
KR102651291B1 (ko) 2015-08-18 2024-03-26 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
CN108350421A (zh) 2015-09-08 2018-07-31 大日本住友制药株式会社 用于制备视网膜色素上皮细胞的方法
EP3347457B1 (en) 2015-09-08 2021-10-27 FUJIFILM Cellular Dynamics, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
AU2016321170B2 (en) 2015-09-08 2022-09-01 Fujifilm Cellular Dynamics Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells
US10947502B2 (en) 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
CN106609263B (zh) * 2015-10-22 2020-04-07 同济大学 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法
CN106609255B (zh) * 2015-10-22 2019-11-05 同济大学 含pj34和视网膜色素上皮细胞的细胞悬液及其应用
CN106609257B (zh) * 2015-10-22 2020-04-10 同济大学 高效分离体外诱导的rpe细胞和rpc的方法
CN106609256B (zh) * 2015-10-22 2020-04-07 同济大学 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法
CN106282096A (zh) * 2016-10-19 2017-01-04 江苏艾尔康生物医药科技有限公司 一种人类视网膜色素上皮细胞层的分离培养方法
EP3594322A4 (en) 2017-03-08 2021-01-27 Sumitomo Dainippon Pharma Co., Ltd. RETINAL PIGMENTARY EPITHELIAL CELL PRODUCTION PROCESS
JP2020511539A (ja) * 2017-03-16 2020-04-16 リネージ セル セラピューティクス インコーポレイテッド 網膜疾患治療法の治療効果を測定する方法
EP4083063A3 (en) 2017-04-18 2023-01-04 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
CN111094548A (zh) * 2017-09-14 2020-05-01 国立研究开发法人理化学研究所 基于背侧化信号转导物质或腹侧化信号转导物质的增加视锥细胞或视杆细胞的方法
CA3082080A1 (en) 2017-11-15 2019-05-23 Friedrich Miescher Institute For Biomedical Research Primate retinal pigment epithelium cell-specific promoter
CN108029638B (zh) * 2017-12-04 2020-04-21 四川省人民医院 一种视网膜色素变性疾病动物模型的构建方法及应用
US11946069B2 (en) 2018-03-12 2024-04-02 RxCell, Inc. Method for generating multiple cellular products from single pluripotent cell source
KR20220004097A (ko) 2019-04-26 2022-01-11 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 신경 망막과 망막 색소 상피 세포와 하이드로겔을 포함하는 복합체 및 그의 제조 방법
KR20220106965A (ko) 2019-10-30 2022-08-01 아스텔라스 인스티튜트 포 리제너러티브 메디슨 망막 색소 상피 세포의 생성 방법
RU2730937C1 (ru) * 2019-11-01 2020-08-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия
WO2022191216A1 (ja) 2021-03-09 2022-09-15 国立研究開発法人理化学研究所 低免疫原性網膜色素上皮細胞の製造方法
CN118302517A (zh) 2021-11-19 2024-07-05 国立研究开发法人理化学研究所 片状视网膜组织的制造方法
CN118871141A (zh) 2022-03-16 2024-10-29 住友制药株式会社 移植用介质
CN119384700A (zh) 2022-04-15 2025-01-28 艾斯本神经科学公司 细胞分化状态的分类方法和分化细胞的相关组合物
JPWO2024172043A1 (cg-RX-API-DMAC7.html) 2023-02-14 2024-08-22

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196923T1 (de) 1993-04-30 2000-10-15 Photogenesis Inc Transplantation des retinalen pigmentepithels
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
CA2317115A1 (en) 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
EP1066368A4 (en) 1998-03-02 2002-08-21 Compucyte Corp SELECTIVE CELL ANALYSIS
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AU782846B2 (en) 1999-10-28 2005-09-01 University Of Massachusetts Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues
JP3454206B2 (ja) * 1999-11-10 2003-10-06 三菱電機株式会社 雑音抑圧装置及び雑音抑圧方法
JP2003533976A (ja) 2000-01-07 2003-11-18 オレゴン ヘルス アンド サイエンス ユニバーシティ 胚分割による霊長類子孫のクローン性増殖
US6602711B1 (en) * 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
CN1311081C (zh) 2000-08-19 2007-04-18 爱克斯澳迪亚有限公司 干细胞分化
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
WO2002092756A2 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
US7425448B2 (en) 2001-07-12 2008-09-16 Geron Corporation Cardiomyocyte precursors from human embryonic stem cells
CA2468292A1 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
WO2003049773A1 (en) 2001-12-11 2003-06-19 Fibrogen, Inc. Methods for inhibiting ocular processes
EP1495120B1 (en) 2002-04-18 2012-10-10 Acuity Pharmaceuticals, Inc Means and methods for the specific modulation of target genes in the eye
US7422736B2 (en) * 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
US7824671B2 (en) 2002-10-04 2010-11-02 Tissuetech, Inc. Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
JP4348706B2 (ja) * 2002-10-08 2009-10-21 日本電気株式会社 アレイ装置および携帯端末
US20040133095A1 (en) 2002-11-14 2004-07-08 Dunki-Jacobs Robert J. Methods and devices for detecting abnormal tissue cells
US20050032126A1 (en) 2003-03-03 2005-02-10 Coombs James H. Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
EP4248752A3 (en) 2004-01-23 2024-01-03 President And Fellows Of Harvard College Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP1812554A4 (en) 2004-11-04 2008-10-08 Advanced Cell Tech Inc DERIVATION OF EMBRYONAL STEM CELLS
EP2048227B1 (en) 2005-02-11 2015-08-19 Agency For Science, Technology And Research Methods for proliferating stem cells
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
WO2008129554A1 (en) 2007-04-18 2008-10-30 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
KR101849329B1 (ko) 2007-10-12 2018-04-16 아스텔라스 인스티튜트 포 리제너러티브 메디슨 Ｒｐｅ 세포의 개선된 생산 방법 및 ｒｐｅ 세포의 조성물
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090233324A1 (en) 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
US8652123B2 (en) 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
HUE054517T2 (hu) 2010-07-23 2021-09-28 Astellas Inst For Regenerative Medicine Eljárások sejtek ritka alpopulációinak detektálására és nagymértékben tisztított sejtkészítmények
JP6200883B2 (ja) 2011-04-29 2017-09-20 ユニヴァーシティー オブ サザン カリフォルニア ポリマー基質上の幹細胞由来網膜色素上皮細胞の低温保存方法
IL320536A (en) 2011-11-14 2025-06-01 Astellas Inst For Regenerative Medicine Pharmaceutical preparations of human RPE cells and their use
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
US9458428B2 (en) 2012-06-05 2016-10-04 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells

Also Published As

Publication number Publication date
AU2013201791B2 (en) 2016-08-18
KR20120051754A (ko) 2012-05-22
MX343606B (es) 2016-11-11
EP4248752A2 (en) 2023-09-27
KR101398356B1 (ko) 2014-05-23
AU2010249263A1 (en) 2011-01-06
AU2013201791A1 (en) 2013-04-11
EP2438814A2 (en) 2012-04-11
US20150328261A1 (en) 2015-11-19
CN1968608A (zh) 2007-05-23
CN102204930A (zh) 2011-10-05
AU2005207042A1 (en) 2005-08-04
KR20070069087A (ko) 2007-07-02
JP2019217356A (ja) 2019-12-26
JP2018086274A (ja) 2018-06-07
ES2721174T3 (es) 2019-07-29
SG155236A1 (en) 2009-09-30
US9040770B2 (en) 2015-05-26
EP1708575A4 (en) 2009-07-01
CN102204930B (zh) 2014-12-03
US20180064761A1 (en) 2018-03-08
US20100299765A1 (en) 2010-11-25
US7736896B2 (en) 2010-06-15
EP2438816A2 (en) 2012-04-11
JP2022153630A (ja) 2022-10-12
IL267126B (en) 2022-04-01
US20110117062A1 (en) 2011-05-19
WO2005070011A3 (en) 2005-10-13
MX375065B (es) 2025-03-06
SG10201912182UA (en) 2020-02-27
EP4248752A3 (en) 2024-01-03
AU2010249263B2 (en) 2013-04-18
IL267126A (en) 2019-08-29
SG188122A1 (en) 2013-03-28
JP2014079650A (ja) 2014-05-08
HK1162931A1 (en) 2012-09-07
AU2019200513A1 (en) 2019-02-14
JP2016195862A (ja) 2016-11-24
EP2438816B1 (en) 2019-03-27
SG10201606441SA (en) 2016-09-29
EP4248751A2 (en) 2023-09-27
CN104434979A (zh) 2015-03-25
IL291162A (en) 2022-05-01
US7795025B2 (en) 2010-09-14
WO2005070011A2 (en) 2005-08-04
HK1216068A1 (en) 2016-10-14
IL177015A0 (en) 2006-12-10
AU2005207042B2 (en) 2010-09-09
EP2929782A1 (en) 2015-10-14
CA2937099A1 (en) 2005-08-04
US9649340B2 (en) 2017-05-16
AU2016259323A1 (en) 2016-12-01
CA2555370A1 (en) 2005-08-04
HK1207821A1 (en) 2016-02-12
KR20130025953A (ko) 2013-03-12
CN1968608B (zh) 2011-06-29
EP4248751A3 (en) 2023-11-01
EP2438814A3 (en) 2012-10-03
EP4269561A2 (en) 2023-11-01
CA2555370C (en) 2024-02-06
EP2438815A3 (en) 2012-10-03
MX2020009456A (es) 2020-10-12
JP2007522131A (ja) 2007-08-09
US20070031386A1 (en) 2007-02-08
JP2012148085A (ja) 2012-08-09
IL177015B (en) 2019-06-30
EP1708575A2 (en) 2006-10-11
KR101258292B1 (ko) 2013-04-25
EP4269561A3 (en) 2024-01-03
JP2015096556A (ja) 2015-05-21
US20060018886A1 (en) 2006-01-26
BRPI0507074A (pt) 2007-06-19
EP2438816A3 (en) 2012-10-03
EP2438815A2 (en) 2012-04-11
JP2024038460A (ja) 2024-03-19
NZ548929A (en) 2010-10-29
US9730962B2 (en) 2017-08-15
JP2020146575A (ja) 2020-09-17
AU2021200601A1 (en) 2021-03-04
AU2016259323B2 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MX375061B (es) Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina.
WO2006080952A3 (en) Improved modalities for the treatment of degenerative diseases of the retina
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EP2279247A4 (en) STEM CELLS OF THE RETINAL PIGMENTARY EPITHELIUM
WO2009134371A3 (en) Composite lacrimal insert and related methods
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
CR11561A (es) Proteinas de union a antigenos
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
WO2007044534A3 (en) Vegf analogs and methods of use
WO2020093018A8 (en) A codon optimized otoferlin aav dual vector gene therapy
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
NZ602479A (en) Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion
DE502005008759D1 (de) In vitro aus knochenmarkstammzellen differenzierteerwendung
WO2011009193A8 (en) Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies
WO2013067076A3 (en) Methods and compositions for neuroprotection
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2007088051A3 (en) Modulation of mdl-1 activity for treatment of inflammatory disease
CL2009001377A1 (es) Compuestos derivados de 3-azabiciclo[3.1.0]hexano; procedimiento de preparacion; compuestos intermediarios; composiciones farmaceuticas que los contienen, utiles en el tratamiento de trastornos del sueno, del humor, enfermedad del alzheimer, apatia y/o estados depresivos, entre otros.